| Literature DB >> 34336691 |
Xiaopan Xu1, Huanjun Wang2, Yan Guo2, Xi Zhang1, Baojuan Li1, Peng Du1, Yang Liu1, Hongbing Lu1.
Abstract
Urinary bladder cancer (BCa) is a highly prevalent disease among aged males. Precise diagnosis of tumor phenotypes and recurrence risk is of vital importance in the clinical management of BCa. Although imaging modalities such as CT and multiparametric MRI have played an essential role in the noninvasive diagnosis and prognosis of BCa, radiomics has also shown great potential in the precise diagnosis of BCa and preoperative prediction of the recurrence risk. Radiomics-empowered image interpretation can amplify the differences in tumor heterogeneity between different phenotypes, i.e., high-grade vs. low-grade, early-stage vs. advanced-stage, and nonmuscle-invasive vs. muscle-invasive. With a multimodal radiomics strategy, the recurrence risk of BCa can be preoperatively predicted, providing critical information for the clinical decision making. We thus reviewed the rapid progress in the field of medical imaging empowered by the radiomics for decoding the phenotype and recurrence risk of BCa during the past 20 years, summarizing the entire pipeline of the radiomics strategy for the definition of BCa phenotype and recurrence risk including region of interest definition, radiomics feature extraction, tumor phenotype prediction and recurrence risk stratification. We particularly focus on current pitfalls, challenges and opportunities to promote massive clinical applications of radiomics pipeline in the near future.Entities:
Keywords: histopathological phenotype; multimodal imaging; radiomics; recurrence; urinary bladder cancer
Year: 2021 PMID: 34336691 PMCID: PMC8321511 DOI: 10.3389/fonc.2021.704039
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Application of CT and mpMRI for the preoperative prediction of the muscle invasion status of BCa. A lesion of a patient confirmed with NMIBC is discernible on Contrast-enhanced CT (CECT) image (A), but the boundaries and basal part of this lesion is rarely distinguishable. The mpMRI (B) including the T2WI, DCE, DWI and its corresponding ADC map can provide more important signs and information like the stalk at the tumor base and submucosal linear enhancement (SLE) for accurate diagnosis of muscle-invasive status (MIS) of BCa (38).
Figure 2Overall workflow of the radiomics strategy for decoding BCa phenotype and recurrence risk.
Figure 3Structure diagram of the multiregion of bladder on the noninvasive image.
Related studies and methodology of CT-/MRI-based bladder image segmentation during the past 20 years.
| Study | Imaging | Approach or strategy | Region focused | Performance and Merits |
|---|---|---|---|---|
| Li et al., 2004 ( | Multispectral MRI | Partial volume (PV) scheme | IB | More information extracted from the multispectral images, and feasible for the IB. |
| Li et al., 2008 ( | Multispectral MRI | Markov random field (MRF) | IB | Realizing the inhomogeneity correction and overcoming the influence of partial volume and bias field. |
| Duan et al., 2010 ( | T1WI | Coupled level-sets | *IB/OB | Realizing the simultaneous extraction of both IB and OB of the bladder. |
| Garnier et al., 2011 ( | T2WI | 3D deformable model based on active region growing strategy | IB/OB | Achieving good performance for the IB segmentation when tumors were not existed in the bladder lumen. |
| Duan et al., 2011 ( | T1WI | Coupled level-sets + volume-based features | Tumor | Realizing the automatic detection of BCa. |
| Duan et al., 2012 ( | T1WI | Coupled level-sets + volume-based features + Adaptive window-setting scheme | Tumor | Realizing the automatic detection and extraction of BCa. |
| Ma et al., 2011 ( | T2WI | Geodesic active contour (GAC) + shape-guided Chan-Vese | IB/OB | Achieving good segmentation performance for both bladder borders without tumor regions using two datasets with 2D images. |
| Han et al., 2013 ( | T1WI | Adaptive MRF with coupled level-set constraints | IB/OB | Fast convergence, robustness to initial estimates, and robustness against noise contaminations, as well as local shape variations of the bladder wall. |
| Qin et al., 2014 ( | T2WI | Coupled directional level-sets with adaptive shape prior constraints | IB/OB | With the average DSC of 0.96 and 0.946, respectively, for the IB and OB segmentation using 11 datasets. |
| Cha et al., 2014 ( | #CECT | Conjoint level set analysis and segmentation system (CLASS) | IB/OB | With the average DSC of 0.842 for the IB segmentation using 182 datasets. |
| Dolz et al., 2018 ( | T2WI | Progressive dilated convolution-based U-NET model | IB/OB/Tumor | With the average DSC of 0.9836, 0.8391 and 0.6856, respectively, for the IB, OB and tumor region segmentation using 60 datasets. |
| Gordon et al., | CECT | Deep-learning convolutional neural network (DL-CNN) | IB/OB | With the average DSC of 0.9869 and 0.875, respectively, for the IB and OB segmentation using 172 datasets. |
| Ma et al., 2019 ( | CECT | U-Net–based deep learning approach (U-DL) | IB | With the average DSC of 0.934 for the IB segmentation using 173 datasets. |
*IB and OB represent the inner and outer borders of bladder, respectively.
#CECT indicates contrast-enhanced CT.
Figure 4Future framework of simultaneous segmentation of the multi-target regions from the bladder mpMRI. The Gt_class_id, Gt_boxes, and Gt_masks represent the ground truth of the multiregion anatation, position of the regions to be detected and focused, and segmentation mask (94).
Related studies and strategies of CT-/MRI-based BCa grading during the past 20 years.
| Study | Patient | Imaging | Target | Approach or strategy | Results and findings | |
|---|---|---|---|---|---|---|
| Tuncbilek et al., 2009 ( | 24 patients from single center | DCE | Tumor | Extracting | Emax/1and | |
| Avcu et al., 2011 ( | 63 patients from single center | DWI | Tumor |
| The | |
| Rosenkrantz et al., 2013 ( | 37 patients from double centers | T2WI, | Tumor |
|
| |
| Kobayashi et al., 2014 ( | 132 patients from single center | DWI | Tumor |
|
| |
| Sevcenco et al., 2014 ( | 43 patients from single center | DWI | Tumor |
|
| |
| Sevcenco et al., 2014 ( | 41 patients from single center | DWI | Tumor |
|
| |
| Wang et al., 2014 ( | 30 patients from single center | DWI | Tumor and referenced regions like urine |
| The performance of using the | |
| Zhang et al., 2017 ( | 128 patients from single center | *CECT | Tumor | Six texture features, including |
| |
| Mammen et al., 2017 ( | 48 patients from single center | CT | Tumor | Texture features including | Only entropy showed significant inter-group differences, and it achieved an AUC of 0.83 in differentiation of low- and high-grade BCa. | |
| Zhang et al., 2017 ( | 61 patients form single center | DWI | Tumor | 102 radiomics features, including the histogram and GLCM features | The model developed could achieve favorable performance for BCa grading, with the AUC of 0.861, significantly better than that of using the ADC value alone. | |
| Wang et al., 2019 ( | 100 patients from single center | T2WI, | Tumor | 924 features were extracted, including morphological features and six categories of texture features like histogram features, GLCM features, *GLRLM features, *GLSZM features, *NGTDM features, and *GLDM features. | The multi-modal MRI-based radiomics approach has the potential in preoperative grading of BCa, with the AUC of 0.9276. | |
| Wang et al., 2020 ( | 58 patients from single center | T2*-weighted imaging and DWI | Tumor |
|
| |
| Zhang et al., 2020 ( | 145 patients from single center | CT | Tumor | 1316 radiomics features, involving | The proposed radiomics model achieved a good performance, with AUC of 0.85 using the testing cohort. | |
*CECT indicates the contrast enhanced CT.
*GLRLM indicates the gray-level run length matrix; GLSZM indicates the gray-level size zone matrix; NGTDM indicates the neighborhood gray tone difference matrix; GLDM indicates the gray-level dependence matrix.
Related studies and strategies of CT-/MRI-based BCa staging and MIS prediction during the past 20 years.
| Study | Patient | Imaging | Target | Approach or strategy | Results and findings |
|---|---|---|---|---|---|
| Hayashi et al., 2000 ( | 71 patients from single center | DCE | Tumor |
|
|
| Takeuchi et al., 2009 ( | 40 patients with 52 bladder tumors from single center | T2WI, DWI, DCE | Tumor |
| The overall accuracy of T stage diagnosis was 67% for T2WI alone, 88% for T2WI+ DWI, 79% for T2WI+DCE, and 92% for all three image types together. |
| Rosenkrantz et al., 2013 ( | 37 patients from double centers | T2WI, | Tumor |
| High-stage (≥ T2) tumors showed greater tumor diameter and lower mean ADC value than the low-stage (≤ T1) tumors. The AUC for MIS prediction was 0.804 by jointly using the tumor diameter and mean ADC value. |
| Kobayashi et al., 2014 ( | 132 patients from single center | DWI | Tumor |
|
|
| Sevcenco et al., 2014 ( | 43 patients from single center | DWI | Tumor |
|
|
| Wang et al., 2016 ( | 59 patients from single center | T2WI, DWI, DCE | Tumor |
| The staging accuracy of DWI was 91.3%. When combining with DCE, the accuracy was improved to 94.6%. |
| Xu et al., 2017 ( | 68 patients from a single center | T2WI | Tumor | *A total of 63 three-dimensional radiomics features, including the histogram-based features and GLCM features, were extracted from the original images and their high-order derivative maps in association with the Student’s | 13 features were finally selected, with an optimal AUC of 0.8610 for MIS diagnosis, which for the first time introduced the radiomics strategy into the preoperative MIS identification and demonstrated its feasibility. |
| Wu et al., 2017 ( | 118 patients from single center | CT | Tumor | # A radiomics signature was determined by the optimal features selected from the original 150 radiomics features uing the LASSO approach. In combination with the clinical factors, a radiomics nomogram was then developed. | The radiomics nomogram showed good discrimination in training and validation cohorts for the prediction of lymph node metastasis, with the AUC of 0.9262 and 0.8986, respectively. |
| Panebianco et al., 2018 ( | / | T2WI, DWI, ADC, DCE | Tumor and submucosal layer | Quantitatively scoring the imaging signs like tumor shape, stalk and SLE on the multiparametric MRI. | The Vesical Imaging-Reporting and Data System (VI-RADS) could be a standard and useful tool to half quantify these imaging signs on the multiparametric MRI for BCa staging and MIS diagnosis. |
| Wu et al., 2018 ( | 103 patients from single center | T2WI | Tumor | A radiomics signature was determined by nine optimal features selected from the original 718 radiomics features uing the LASSO approach. In combination with the clinical factors, a radiomics nomogram was then developed. | The radiomics signature achieved the AUC of 0.8447 for the prediction of lymph node metastasis. And the nomogram consisted of the radiomics signature with the clinical factors achieved more favorable performance, with the AUC improved to 0.8902 in the validation cohort. |
| Xu et al.,2019 ( | 54 patients from single center | T2WI, DWI, ADC | Tumor | Radiomics features like histogram-based, GLCM and GLRLM features were extracted from the multimodal MRI data with the multi-grayscale normalization strategy. | The optimal 19 features derived from the three modalities finally achieved the best performance, with the AUC of 0.9756 for MIS diagnosis, indicating the great capacity of the multimodal MRI-based radiomics strategy for the preoperative MIS identification. |
| Zheng et al., 2019 ( | 199 patients from single center | T2WI | Tumor and basal part | 2602 radiomics features were extracted from both the tumorous region and basal part of the images. A radiomics signature was determined uing the LASSO approach. In combination with the clinical factors, a radiomics nomogram was then developed. | The radiomics signature showed good performance in MIS prediction. Integrating with the clinical factor, nomogram achieved much better diagnostic power, with the AUC improved to 0.876 in the validation cohort. |
| Barchetti et al., 2019 ( | 78 patients from single center | T2WI, DWI, ADC, DCE | Tumor and submucosal layer | VI-RADS | The VI-RADS achieved favorable performance for MIS diagnosis, with the AUC of 0.926 and 0.873 when conducted by reader 1 and 2, respectively. |
| Ueno et al., 2019 ( | 74 patients from single center | T2WI, DWI, ADC, DCE | Tumor and submucosal layer | VI-RADS | The VI-RADS achieved favorable performance for MIS diagnosis, with pooled AUC of 0.90 when conducted by five readers. |
| Wang et al., 2019 ( | 340 patients from single center | T2WI, DWI, ADC, DCE | Tumor and submucosal layer | VI-RADS | The VI-RADS achieved excellent performance for MIS diagnosis, with the AUC of 0.94 when conducted by two readers in consensus. |
| Wang et al., 2020 ( | 106 patients from double centers | T2WI, DWI, ADC | Tumor | 1404 radiomics features were extracted. A radiomics signature was generated using the SVM-RFE and logistic regression. A nomogram was then developed using the signature and MRI-determined tumor stalk. | The signature alone achieved a good performance in MIS prediction. The nomogram integrating with the signature and tumor stalk achieved much better diagnostic performance, with the AUC improved to 0.877 in the validation cohort. |
*SVM-RFE indicates the support vector-machine-based recursive feature elimination algorithm.
#LASSO indicates the least absolute shrinkage and selection operator algorithm for feature selection.
Figure 5Treatment recommendations for BCa patients based on the MIS, grade and recurrence risk stratification.
Related studies and strategies of BCa recurrence risk prediction during the past 20 years.
| Study | Patient | Treatment | Follow-up/years | Predictionmodel | Findings | Conclusion |
|---|---|---|---|---|---|---|
| Sylvester et al., 2006 ( | 2596 NMIBC patients from 7 EORTC trials | TURBT + Intravesical treatment (78.4% of the patients) | Median follow-up of 3.9 years and maximum follow-up of 14.8 years | Univariate and multivariate analyses | The EORTC risk table was derived based on the number and size of tumors, prior recurrence rate, T category, carcinoma in situ, and grade. | EORTC risk table is a useful tool for the urologist to discuss the different options with the patient to determine the most appropriate treatment and frequency of follow-up. |
| Fernandez et al., 2009 ( | 1062 NMIBC patients from 4 CUETO trials | TURBT + BCG with 12 instillations | 5 years | Univariate and multivariate analyses | The CUETO risk table was developed using gender, age, grade, tumor status, multiplicity and associated Tis. | The recurrence risks calculated by the CUETO table were lower than those obtained with EROTC table. |
| Seo et al., 2010 ( | 251 patients from single center | TURBT + full-doze maintenance BCG | 5 years and 9 months | EORTC | C-index: 0.62 | The recurrence rate and progression rate were almost similar to the EORTC risk tables. However, the recurrence rate was low in the intermediate-risk group. |
| Xylinas et al., 2013 ( | 4784 patients from 8 centers | TURBT +51% cohort of immediate single postoperative chemotherapy + 11% cohort of BCG | 4 years and 9 months | EORTC, CUETO | C-index: 0.60, 0.52 | Both models exhibited poor discrimination. Specific biomarkers should be exploited for improving the performance. |
| Xu et al., 2013 ( | 363 NMIBC patients from single center | TURBT +79% cohort of immediate single postoperative chemotherapy + 100% cohort of the entire course of intravesical chemotherapy | 3 years | EORTC, CUETO | C-Index: 0.71, 0.66 | The EORTC model showed more value in predicting recurrence and progression in patients with NMIBC. |
| Kohjimoto et al., 2014 ( | 366 NMIBC patients from single center | TURBT + BCG | 5 years | EORTC, CUETO | C-index: 0.51, 0.58 | Although both exhibited poorly for recurrence prediction, CUETO was a little better. |
| Vedder et al., 2014 ( | 1892 NMIBC patients from 18 centers | TURBT +13~22% cohort of the entire course of intravesical chemotherapy+17~30% cohort of BCG + 0.55~0.61% cohort of Re-TURBT | 10 years | EORTC, CUETO | C-index: 0.56-0.59, | The discriminatory ability for BCa recurrence was unsatisfactory. |
| Cambier et al., 2016 ( | 1812 NMIBC patients from 2 EORTC trials | TURBT + 1~3 years of maintenance BCG | 7 years 5 months | Updated EORTC | C-index: 0.59. | NMIBC patients treated with1~3 years of maintenance BCG had a heterogeneous prognosis among the high-risk patients, and early cystoscopy should be considered. |
| Dalkilic et al., 2018 ( | 400 NMIBC patients from single center | TURBT + BCG (45.3% of the patients) | 5 years | EORTC, CUETO | C-index: 0.777, 0.703 | EORTC risk table was better than the CUETO table for the recurrence prediction. |
| Kim et al., 2019 ( | 970 NMIBC patients from single center | TURBT + BCG | 5 years | New model, EORTC | AUC: 0.65, 0.56 | The new model developed by using gross hamartia, previous or concomitant upper urinary tract urothelial carcinoma, stage, grade, number of tumors, intravesical treatment performed better than the EORTC risk table. |
| Yajima et al., 2019 ( | 91 NMIBC patients from single center | TURBT | 5 years | Inchworm sign (tumor stalk) on the DWI and ADC images | The progression rate of inchworm-sign-negative cases was significantly higher than that of inchworm-sign-positive cases, whereas there was no significant difference in the recurrence rate between two groups. | The absence of an inchworm sign and histological grade 3 were independent risk factors for progression. |
| Xu et al., 2019 ( | 71 patients including 36 NMIBC patients and 35 MIBC patients | TURBT for the NMIBC patients and RC for the MIBC patients | 2 years | Radiomics nomogram developed based on the radiomics features extracted from T2WI, DWI, ADC, and DCE MRI data, and the clinical risk factors | The proposed radiomics nomogram exhibited good performance both in the training cohort (AUC: 0.915) and the validation cohort (AUC: 0.838) for the prediction of the BCa recurrence during 2 years after operation. | The proposed radiomics-clinical nomogram has potential in the preoperative prediction |
Figure 6A potential definition of the invasive depth of bladder tumor based on the BWT distribution on the bladder wall region.